Intravitreal Bevacizumab in a Patient With Neovascular Glaucoma

Abstract
Ophthalmic Surgery, Lasers and Imaging Retina | The utility of intravitreal bevacizumab injection in a patient with neovascular glaucoma following central retinal vein occlusion is explored. Bevacizumab (1 mg in 0.04 mL) was used after failed intraocular pressure (IOP) control with transscleral cyclophotocoagulation and panretinal photocoagulation. IOP improved within 2 days and the patient experienced marked improvement in comfort.